Andrea Ellis

Andrea Ellis, listed as board member, appears in our data through filings on BridgeBio Pharma, Inc. shares, published by SEC (Form 4). In total, 13 filings cover trades dated from 15 March 2022 to 9 July 2026.

On the open market, the record shows 1 purchase worth €92k and 5 sales worth €6.9M. Sales outweigh purchases by €6.8M. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The rest of the record consists of 2 share grants and 5 option exercises. Since January 2026: no purchases and 2 sales on the market.

On 13 July 2026 came the latest disclosure, an option exercise for €252k in BridgeBio Pharma, Inc. The clock since the last published purchase (17 March 2022) now reads 1,698 days. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.